Begin patient screening for the Phase 2a study of simufilam
Deadline not yet reached (155 days left)
- Announced
- 22 Sep 2026
- Due
- 31 Mar 2027
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Patient screening for the Phase 2a study is expected to begin by the first quarter of 2027”
What we found
The deadline has not passed yet, so there is nothing to check. We look for evidence starting 30 days after 31 Mar 2027.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical milestone
- Indicative materiality
- Medium rules
- Action
- Begin
- Deliverable
- Phase 2a study patient screening
- Where
- United States
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- Medium
- Specificity
- High
- Conditional
- Yes: subject to clinical trial site engagement and patient enrollment
- Depends on
- Customer
Tell me what happens
This deadline has not been settled yet. We check 30 days after it passes. Get an email when we record the outcome.
How this entry was checked
- Commitment recordedRecorded from the company's filing.
- OutcomeNot yet assessed. Nothing is judged before the deadline.
Are you Filana Therapeutics, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2026-FLNA-000106 · Corrections policy